Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company focused on developing and commercializing innovative eye health products. Utilizing its proprietary sol-gel drug delivery platform, the company aims to enhance the effectiveness and convenience of treatments for various ocular conditions. Sol-Gel collaborates with other pharmaceutical firms and healthcare providers to bring advanced eye care solutions to market.
Company News
Over 22 pharmaceutical companies are developing new drugs for basal cell neoplasms, with promising therapies targeting various molecular pathways and showing potential in clinical trials.
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
On Thursday, 369 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Coca-Cola (NYSE:KO). The smallest company by market cap to hit a new 52-week low was Neptune Wellness Solns (NASDAQ:NEPT). Aethlon Medical (NASDAQ:AEMD)'s stock fell the most, as it...
